drugset
drugset / Trial / NCT05280509

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

NCT05280509 ↗

Phase 1/2 Recruiting 70 enrolled Telios Pharma, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.

Timeline

Start
2022-06-09
Primary completion
2025-10
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject TL-895 Small molecule 150 mg Oral
Subject TL-895 Small molecule 300 mg Oral
Subject TL-895 Small molecule 450 mg Oral
Background Ruxolitinib Small molecule — Oral

Indications

myelofibrosis primary myelofibrosis